VAPO - Vapotherm, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
10.06
-0.18 (-1.76%)
At close: 4:02PM EDT

10.06 0.00 (0.00%)
After hours: 4:17PM EDT

Stock chart is not supported by your current browser
Previous Close10.24
Open10.18
Bid10.00 x 1100
Ask10.06 x 800
Day's Range9.85 - 10.33
52 Week Range8.30 - 24.63
Volume72,341
Avg. Volume208,558
Market Cap176.044M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.38
Earnings DateNov 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.33
Trade prices are not sourced from all markets
  • Business Wire

    Vapotherm to Report Third Quarter 2019 Financial Results

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the third quarter of 2019 after the close of trading on Tuesday, November 5, 2019. Vapotherm’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.

  • GuruFocus.com

    Vapotherm Inc (VAPO) President & CEO Joseph Army Bought $100,000 of Shares

    President & CEO of Vapotherm Inc (30-Year Financial, Insider Trades) Joseph Army (insider trades) bought 10,000 shares of VAPO on 09/04/2019 at an average price of $10 a share. Continue reading...

  • Zacks.com featured highlights include: ACM, K12, Vapotherm, Equity Commonwealth and Columbus McKinnon
    Zacks

    Zacks.com featured highlights include: ACM, K12, Vapotherm, Equity Commonwealth and Columbus McKinnon

    Zacks.com featured highlights include: ACM, K12, Vapotherm, Equity Commonwealth and Columbus McKinnon

  • New Analyst Coverage Puts Spotlight on These 5 Stocks
    Zacks

    New Analyst Coverage Puts Spotlight on These 5 Stocks

    Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

  • What Percentage Of Vapotherm, Inc. (NYSE:VAPO) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Vapotherm, Inc. (NYSE:VAPO) Shares Do Insiders Own?

    The big shareholder groups in Vapotherm, Inc. (NYSE:VAPO) have power over the company. Large companies usually have...

  • Vapotherm, Inc. (VAPO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Vapotherm, Inc. (VAPO) Q2 2019 Earnings Call Transcript

    VAPO Vapotherm, Inc. (VAPO) Q2 2019 Earnings Call Transcript

  • ACCESSWIRE

    Vapotherm, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Vapotherm, Inc. (NYSE: VAPO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 29, 2019 at 4:30 PM Eastern ...

  • Business Wire

    Vapotherm to Present at the William Blair 39th Annual Growth Stock Conference

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the William Blair 39th Annual Growth Stock Conference on Wednesday, June 5th at the Loews Chicago Hotel in Chicago, Illinois. Vapotherm is scheduled to present at 3:20pm Central Time. A webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.

  • Vapotherm Inc (VAPO) Q1 2019 Earnings Call Transcript
    Motley Fool

    Vapotherm Inc (VAPO) Q1 2019 Earnings Call Transcript

    VAPO earnings call for the period ending March 31, 2019.

  • Business Wire

    Vapotherm to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15 at the Encore Hotel in Las Vegas, Nevada. Vapotherm is scheduled to present at 5:15pm Pacific Time. A webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.

  • Associated Press

    Vapotherm: 1Q Earnings Snapshot

    On a per-share basis, the Exeter, New Hampshire-based company said it had a loss of 76 cents. The medical technology company posted revenue of $12.3 million in the period. For the current quarter ending ...

  • Business Wire

    Vapotherm Reports First Quarter 2019 Financial Results

    Vapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the first quarter ended March 31, 2019.

  • You Might Like Vapotherm, Inc. (NYSE:VAPO) But Do You Like Its Debt?
    Simply Wall St.

    You Might Like Vapotherm, Inc. (NYSE:VAPO) But Do You Like Its Debt?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors are always looking for growth in small-cap stocks like Vapotherm, Inc. (NYSE:VAPO), with a...

  • Business Wire

    Vapotherm to Report First Quarter 2019 Financial Results

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the first quarter of 2019 after the close of trading on Tuesday, May 7, 2019. Vapotherm’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to a live webcast, please visit the Investors section of the Vapotherm’s website at: http://investors.vapotherm.com/events-and-presentations/events.

  • Business Wire

    Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart Failure Patients

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the American Journal of Emergency Medicine, titled “HVNI vs NIPPV in the treatment of Acute Decompensated Heart Failure: subgroup analysis of a multi-center trial in the ED” showed equivalent outcomes between Hi-VNI Technology and Non-invasive Positive Pressure Ventilation (NiPPV) in the treatment of respiratory distress in a subgroup of patients suffering from acute decompensated heart failure (ADHF). “These results represent another proof point that Vapotherm Hi-VNI Technology is a viable alternative to relieve undifferentiated respiratory distress across a wide variety of patient populations,” said Joe Army, President and CEO.

  • GuruFocus.com

    Vapotherm Inc (VAPO) Files 10-K for the Fiscal Year Ended on December 31, 2018

    For the last quarter Vapotherm Inc reported a revenue of $42.4 million, compared with the revenue of $30.12 million during the same period a year ago. Warning! GuruFocus has detected 1 Warning Sign with VAPO.

  • Associated Press

    Vapotherm: 4Q Earnings Snapshot

    The Exeter, New Hampshire-based company said it had a loss of $1.39 per share. Losses, adjusted to extinguish debt, came to $1.28 per share. The medical technology company posted revenue of $11.7 million ...

  • Business Wire

    Vapotherm Reports Fourth Quarter and Fiscal Year 2018 Financial Results

    2018 Revenue of $42.4 Million Reflects 19.0% Increase Over Prior Year

  • Business Wire

    Vapotherm® Releases Next Generation of Capital Unit: Precision Flow Hi-VNI™ System

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the release of the next generation of its capital unit: the Precision Flow Hi-VNI system. For this generation of the Precision Flow® system, both the hardware and software have been updated to improve reliability, and to comply with the EMC 4th Edition requirements for medical devices, IEC 60601-1-2:2014. As with all the other models of the Precision Flow system, this generation provides Hi-VNI Technology, the innovation that delivers Mask-Free NIV™ for spontaneously breathing patients.